The University of Sydney has appealed a judgment finding it unlawfully terminated a political economy lecturer for showing students a slide of a Nazi swastika superimposed on the Israeli flag.
The founder of investment group Mayfair 101 must foot half his costs of a successful appeal of a 20-year ban on fund raising because of the many “spurious” grounds of appeal he pressed.
Ashurst has lured a partner from Hall & Wilcox as the firm looks to expand its Sydney real estate team.
The maker of Vagisil personal care products has filed a trade mark suit against pharmaceuticals and cosmetic company Dr Wolff over its new line of Vagisan products, arguing the name is likely to confuse consumers.
Despite recent class actions against Medibank and Optus for cybersecurity breaches, class actions over cyber attacks will not become common because they involve “a lot of work for not a lot of money”, a lawyer has predicted.
A judge has hit Alkaloids of Australia with a nearly $2 million penalty for engaging in cartel conduct and sentenced its former export manager to a term of imprisonment for his involvement in fixing prices for a key chemical in anti-spasmodic drug Buscopan.
Ashurst will open an office in Seoul through after a joint venture with a local firm won approval in a legal market first.
Infant formula maker Care A2 Plus has launched an attack on A2 Milk, filing a lawsuit arguing the dairy giant’s trade marks should be cancelled because they’re too generic and are being used to sell products that don’t exclusively contain the a2 protein.
The maker of Finish dishwashing products has appealed a judgment that removed two of its trade marks for non-use and rejected its claim that a competitor’s logo was deceptively similar.
Swiss pharmaceutical company Biogen and Australian generic drug maker Pharmacor have dropped their claims against one another in a lawsuit over the patent for MS drug Tecfidera. In an October 14 order by Federal Court Justice Helen Rofe, Biogen’s infringement claims and Pharmacor’s cross-claims seeking to invalidate the lucrative patent were discontinued by consent without…